The percentage of CD19+/CD5+/TLR2+ in CLL patients was diverse and significantly higher (p < 0.05) in patients at stage 0 (median: 0.52%) as compared to the stages I–II (median 0.29%) and III-IV (median 0.30%) according to Rai stages (Table 2). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.